Who are Linagliptin and Basal Insulin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/linagliptin-and-basal-insulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Linagliptin and Basal Insulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Linagliptin and Basal Insulin (Linagliptin and Basal Insulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor combined with basal insulin. Area: Diabetes.

phase 3 DPP-4 inhibitor combined with basal insulin DPP-4 (dipeptidyl peptidase-4) and insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Linagliptin and Basal Insulin (Linagliptin and Basal Insulin) — Rabin Medical Center. Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while basal insulin provides long-acting glucose lowering.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Linagliptin and Basal Insulin TARGET	Linagliptin and Basal Insulin	Rabin Medical Center	phase 3	DPP-4 inhibitor combined with basal insulin	DPP-4 (dipeptidyl peptidase-4) and insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor combined with basal insulin class)

Rabin Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Linagliptin and Basal Insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/linagliptin-and-basal-insulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab